TY - JOUR
T1 - Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment with Ipilimumab and Radiation Therapy
AU - Dumbrava, Ecaterina Ileana
AU - Smith, Veronica
AU - Alfattal, Rasha
AU - El-Naggar, Adel K.
AU - Penas-Prado, Marta
AU - Tsimberidou, Apostolia M.
N1 - Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications will expand as immunotherapies are being investigated in various tumors with promising results. Currently, there is inadequate identification of predictive biomarkers of response or toxicity. Unique response patterns include pseudoprogression and delayed response. The use of immune checkpoint inhibitors exhibit an unique toxicity profile, the immune-related adverse events (irAEs). The most notable immune reactions are noted in skin (rash), gastrointestinal track (colitis, hepatitis, pancreatitis), lung (pneumonitis), heart (myocarditis), and endocrine system (thyroiditis, hypophysitis). We present a patient with metastatic adenoid cystic carcinoma of the left submandibular gland with granulomatous inflammation of the lacrimal glands and axonal neuritis of the cervical and paraspinal nerves following treatment with ipilimumab and radiation therapy.
AB - Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications will expand as immunotherapies are being investigated in various tumors with promising results. Currently, there is inadequate identification of predictive biomarkers of response or toxicity. Unique response patterns include pseudoprogression and delayed response. The use of immune checkpoint inhibitors exhibit an unique toxicity profile, the immune-related adverse events (irAEs). The most notable immune reactions are noted in skin (rash), gastrointestinal track (colitis, hepatitis, pancreatitis), lung (pneumonitis), heart (myocarditis), and endocrine system (thyroiditis, hypophysitis). We present a patient with metastatic adenoid cystic carcinoma of the left submandibular gland with granulomatous inflammation of the lacrimal glands and axonal neuritis of the cervical and paraspinal nerves following treatment with ipilimumab and radiation therapy.
KW - axonal neuritis
KW - granulomatous lacrimal glands inflammation
KW - immune checkpoint inhibitors
KW - ipilimumab
UR - http://www.scopus.com/inward/record.url?scp=85047662274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047662274&partnerID=8YFLogxK
U2 - 10.1097/CJI.0000000000000224
DO - 10.1097/CJI.0000000000000224
M3 - Article
C2 - 29787423
AN - SCOPUS:85047662274
SN - 1524-9557
VL - 41
SP - 336
EP - 339
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
IS - 7
ER -